Two glycoforms of recombinant human thrombomodulin (TM; TMD1-105 and TMD1-75), an endothelial cell membrane protein, were tested for their ability to alter thrombin-induced activation of cultured human umbilical vein endothelial cells (HUVECs). After stimulation with 10 nmol/L thrombin, HUVEC generation of inositol-l,4,5-trisphosphate (IP}), a potent Ca^-mobilizing second messenger, was dosedependently blocked by TMD1-105. Both TMD1-105 (IC M = 10 nmol/L) and TMD1-75 (ICjo=100 nmol/L) blocked the enhanced prostacyclin synthesis by HUVEC monolayers treated with 10 nmol/L thrombin. HUVEC monolayer permeability to Evans blue dye-labeled albumin increased from 0.125 ±0.06 /iL/min in control experiments to 0J80±0.09 jtL/min after treatment with 100 nmol/L thrombin (P<.05). Incubation or HUVECs with TMD1-105 alone (600 nmol/L) had no effect (0.114±0.04 fiL/min) on basal permeability. In contrast, incubation of 100 nmol/L thrombin with 600 nmol/L TMD1-105 reduced this increase in HUVEC permeability to almost control levels (0.142±0.06 /tL/min). These results demonstrate that recombinant human TM, a potent in vitro anticoagulant, also functions as an antagonist of thrombin receptor-mediated HUVEC activation. In addition to its anticoagulant functions, the highaffinity endothelial cell receptor TM may play a role in modulating endothelial cell activation by thrombin. and barrier dysfunction through increased macromolecule permeability.
T hrombin plays a central role in thrombosis and
hemostasis by catalyzing the activation of clotting factors V and VIII, by fibrinogen cleavage to form fibrin clots, and by protein C activation. 1 Thrombin is also a ligand for receptor-mediated activation in many cell systems, including the endothelium, 2 -5 where activation responses are evoked and are characterized by increased prostacyclin (PGI 2 ) synthesis, 5 platelet activating-factor synthesis, 6 adhesiveness for neutrophils through expression of adhesion molecules, 7 and barrier dysfunction through increased macromolecule permeability. 8 Although PGI 2 is a potent vasodilator and inhibitor of platelet aggregation, the overall endothelial response to thrombin can be regarded as proinflammatory.
Thrombomodulin (TM), an endothelial cell membrane protein, forms a high-affinity complex with thrombin that catalyzes the formation of activated protein C, a potent anticoagulant. 9 Thrombin-dependent fibrinogen cleavage and activation of clotting factors V and VIII are inhibited by complex formation with TM. 10 To study the structure-function relations, secretable derivatives of human TM have been made by deletion of the transmembrane and cytoplasmic tail domains. These "exodomain" derivatives of human TM have shown potent in vitro anticoagulant activity and in vivo antithrombotic activity in animal models. 14 Given the diverse array of cellular responses to thrombin, it was of interest to determine whether, in addition to altering thrombin's substrate specificity, TM might alter receptor-mediated responses in human endothelium. Our present studies show that two forms of recombinant human TM block activation of human umbilical vein endothelial cells (HUVECs) by human thrombin, suggesting that recombinant human TM may function as an antagonist of thrombin receptor-mediated cellular activation. The results also suggest that cell-surface TM may function in vivo to inhibit propagation of endothelial cell activation by thrombin.
Methods

Soluble TM Variants
Two glycoforms of a secretable deletion mutant of recombinant human TM with relative molecular masses of =105 000 and 75 000 (TMD1-105 and TMD1-75, respectively) were expressed in human 293 cells and purified to homogeneity from conditioned serum-free medium as previously described.
11 Human a-thrombin (2400 US U/g) was a gift from Dr J.W. Fenton II, New York State Department of Health, Albany, NY. Polyclonal rabbit anti-human TM antibody was produced by Berkeley Antibody Co, Richmond, Calif, using purified recombinant human TM comprising the six epidermal growth factor (EGF)-binding domains and expressed in insect cells. The specificity of the serum was confirmed by Western blot analysis against purified recombinant six EGF TM and by inhibition of six EGF TM cofactor activity by use of an amidolytic assay.
11
Human Endothelial Cell Culture
HUVECs were isolated from umbilical veins and cultured as described.
liJ6 Growth medium consisted of medium 199 supplemented with 20% fetal bovine serum (Irvine Scientific, Santa Ana, Calif), 1% penicillin (10,000 U/ml)/streptomycin (10 figlmL) (K.C. Biologicals, Lenexa, Kan), and 2 U/mL heparin (Eli Lilly & Co, Indianapolis, Ind). All experiments were performed on cultures in the first to the fourth passage.
Assay ofInositol Phosphate Metabolites in HUVECs
Thrombin-mediated intracellular generation of inositol-1-phosphate (IP ! ), inositol-1,4-bisphosphate (IP 2 ), inositol-1,4,5-trisphosphate (IP3), and inositol-1,3,4,5-tetrakisphosphate (IP 4 ) were determined in HUVEC extracts using a Vydac nucleotide an ion-exchange highperformance liquid chromatography (HPLC) column, as described previously. 1617 HUVECs were labeled with 10 jiCi/mL [3H]/nyoinositol (New England Nuclear, Boston, Mass) for 48 hours before assay. The increased generation of inositol phosphate metabolites (percent increase over control) was determined after HUVEC treatment with either 10 nmol/L thrombin or thrombin/ TMD1-105 mixtures for 1 minute at 37°C.
PGI 2 Release
HUVECs were plated at confluent density (10 5 cells/ well) in 24-well plates in complete culture medium and allowed to adhere overnight. Monolayers were treated with 10 nmol/L a-thrombin in serum-free medium for 5 minutes at 37°C. Aliquots of serum-free conditioned medium were removed and stored at -70°C until assay. In parallel experiments, various concentrations of recombinant human TM and 10 nmol/L thrombin were preincubated together (5 minutes) before their addition to the cells. PGI2 levels (picograms per 100 microliters) were measured by radioimmunoassay of 6-ketoprostaglandin F l a as we have described.
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Measurement of Evans Blue Dye-Albumin Permeability
Permeability of HUVEC monolayers to macromolecules was assessed spectrophotometrically by determining the clearance of Evans blue dye-labeled bovine serum albumin (EB-BSA) across HUVEC monolayers grown on gelatinized polycarbonate micropore membranes as described previously. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Hanks' balanced salt solution supplemented with 0.5% BSA was present in both luminal and albuminal compartments of a modified che mo taxis chamber. 8 Control clearance rates (microliters per minute) of EB-BSA across the monolayer were determined over 30 minutes. After addition of 100 nmol/L thrombin or thrombin/TMD l-105 mixtures, the experimental clearance rates were determined over the subsequent 60 minutes. Clearance rates were linear over the entire time course of both control and experimental conditions.
Results
Recombinant TM Inhibits a-Thrombin-Stimulated HUVEC Inositol Polyphosphate Generation
HUVEC PGI 2 synthesis and barrier dysfunction after thrombin challenge are dependent on increases in cyto- (Fig 1) . Exposure of HUVECs to 10 nmol/L thrombin for 1 minute resulted in 16±4%, 61±10%, 72±10%, and 49±18% increases in the IP,, IP2, IP 3 , and IP 4 content, respectively, of HUVEC monolayers (n = 4, all values of P<.05). Significant changes in any inositol polyphosphate were not observed when HUVECs were exposed to 100 nmol/L TMD1-105 alone or to 1 to 100 umo\/L BSA. In contrast, incubation of 20, 50, and 100 nmol/L TMD1-105 with 10 nmol/L thrombin resulted in a dramatic dose-dependent inhibition of the thrombinstimulated generation of IP 2 , IP 3 , and IP 4 at all doses of TMD1-105 tested (P<.05 at 50 and 100 nmol/LTMD1-105). Production of IP, was also inhibited but did not reach statistical significance. Inhibition of 10 nmol/L thrombin-induced IP 2 , IP 3 , and IP 4 generation by 100 nmol/L TMD1-105 was 45%, 66%, and 44%, respectively. These results suggest that TMD1-105 is a potent inhibitor of phospholipase C activation and subsequent phosphatidylinositol hydrolysis in thrombin-stimulated HUVECs. The basal rate of PGI 2 synthesis in unstimulated HUVEC monolayers in these experiments was 9.4±1.1 pg/100 /iL (n = 5) over 5 minutes and increased eightfold to 76.8±3.6 pg/100 fit (n = 5) after exposure to 10 nmol/L human thrombin. In addition to TMD1-105, a second form of recombinant TM, TMD1-75, was used to study the effect of TM on the thrombin-stimulated increase in HUVEC PGI 2 synthesis. TMD1-105 differs from TMDl-75 in that it contains chondroitin sulfate, whereas TMDl-75 does not." Furthermore, TMD1-105 and TMDl-75 have dissociation constants (K<£) for bovine thrombin of 3 and 16 nmol/L, respectively.
11 Although neither glycoform nor 1 to 100 jimol/L BSA altered the basal rate of HUVEC PGI 2 synthesis, as shown in Fig 2, both glycoforms produced a dosedependent inhibition of a-thrombin-stimulated PGI 2 synthesis. Consistent with its higher affinity for thrombin, TMD1-105 was a more potent inhibitor of thrombinstimulated HUVEC PGI 2 synthesis than TMDl-75. Equimolar (10 nmol/L) concentrations of TMD1-105 and thrombin resulted in 50% inhibition of thrombinstimulated PGI 2 synthesis. A 10-fold molar excess of TMDl-75 (100 nmol/L) over thrombin was required to accomplish 50% inhibition.
TM Blockade Increases Thrombin-Stimulated HUVEC PGI 2 Release
The results described above suggest that cell-surface TM may function as a high-affinity, competitive inhibitor of thrombin-dependent endothelial cell activation. This concept was tested by measuring thrombin-stimulated PGI 2 synthesis after a 30-minute HUVEC treat- Confluent human umbilical vein endothelial cell monolayers in 24-well plates were pretreated (30 minutes at 37°C) with either buffer alone, preimmune rabbit serum, or anti-human thrombomodulin (TM) antibody (IgG) at a 1:50 dilution. Cells were then stimulated with buffer, a-thrombin, or thrombin receptor-activating peptide (TRAP) for 5 minutes, and the medium was removed for radioimmunoassay of prostacyclin (PGI2; picograms per 100 microliter) as described in "Methods." Data are the mean±SD from three wells and were verified in repetitive experiments (n = 3). In additional experiments, concentrations of TRAP 14 from 0.1 to 10 junol/L did not elicit PGI 2 synthesis and were similarly unaffected by either buffer, preimmune serum, or anti-human TM IgG.
*P<.05.
ment with either preimmune serum or serum containing polyclonal anti-human TM antibody (Table) . PGI 2 synthesis elicited by 10 nmol/L a-thrombin was not enhanced by anti-TM serum, indicating that this represents a maximal effective thrombin concentration. In contrast, anti-human TM-containing serum significantly enhanced 0.5 and 1.0 nmol/L thrombin-stimulated HUVEC PGI 2 synthesis by =70%, whereas preimmune serum did not effect thrombin-stimulated PGI 2 synthesis. Anti-human TM serum did not alter PGI 2 synthesis in response to TRAP 14, the 14-amino acid synthetic peptide (95% pure by reverse-phase HPLC), whose sequence (NH 2 -SFLLRNPNDKEPFC-ONH 2 ) is identical to the cleaved thrombin receptor TV-terminal and directly activates the thrombin receptor by mimicking the tethered receptor ligand. 22 These results suggest that cell-surface TM functions to attenuate thrombinstimulated HUVEC activation.
Recombinant TM Inhibits Thrombin-Stimulated HUVEC Barrier Dysfunction
The rate of EB-BSA clearance (in microliters per minute) across confluent HUVEC monolayers was used to measure permeability to macromolecules. As shown in 
Q5).
Exposure of HUVEC monolayers to 600 nmol/L TMD1-105 alone did not affect permeability to EB-BSA (0.114±0.04, n = 8). However, HUVEC exposure to a mixture of 100 nmol/L thrombin and 200 nmol/L TMD1-105 resulted in a clearance rate that was decreased slightly to 0.302±0.09 (n = 7, P=.O7). Furthermore, a mixture of 100 nmol/L thrombin and 600 nmol/L TMD1-105 resulted in a clearance rate that was significantly attenuated to 0.142±0.06 (n = 8, /"=.01), a level that approached basal clearance rates.
Discussion
Our studies demonstrate that recombinant TM dramatically attenuates several key indices of thrombin- mediated human endothelial cell activation. Interestingly, the inhibition profiles of TMD1-105 and TMDl-75 on thrombin-stimulated PGI 2 synthesis in HUVEC monolayers are similar to those for inhibition of thrombinstimulated serotonin release in platelets, as described previously. 11 Thrombin responses in both endothelium and platelets are mediated via a receptor system that requires the active site of thrombin.
-
21
- 22 However, it was unclear whether the thrombin-TM complex, in which the active site of thrombin is altered but not blocked, would demonstrate diminished activity in activating endothelial cells when compared with native a-thrombin. The thrombin receptor that acts via this serine protease-dependent activation mechanism was recently cloned, and mRNA coding for the thrombin receptor has been detected in both platelets and HUVECs. 22 The Af-terminal region of the receptor contains a thrombin cleavage site at Arg,). Only 13 amino acids from the C-terminal to this cleavage site is a highly anionic sequence (FWEDEEKNES) that is homologous to the C-terminal sequence of sulfated hirudin peptides (DFEEIPEE[Y-SO 3 ]L). These hirudin peptides are known to bind to the anion-binding exosite of thrombin, 23 to block thrombin-mediated platelet and endothelial cell activation, 18 -24 - 25 and to block activation of the cloned thrombin receptor expressed in oocytes. 22 Peptides corresponding to the hirudin-like region of the thrombin receptor have recently been shown to displace C-terminal hirudin peptides from the anion-binding exosite and to allow thrombin's substrate specificity. 26 Several studies have demonstrated that fibrinogen, hirudin, and hirudin C-terminal peptides act as competitive inhibitors of thrombin binding to TM.
-31
The interaction between thrombin and TM can be blocked by TM fragments encoding the fifth and sixth EGF-like repeats 32 as well as synthetic peptides that are homologous to the highly anionic C-loop of the fifth EGF repeat, 33 -34 suggesting that the primary thrombinbinding site is in the fifth EGF repeat, an EGF repeat present in both TMD1-105 and TMDl-75. The enhanced inhibitory activity of TMD1-105 compared with TMDl-75 described in the present studies is most likely due to its higher affinity for thrombin, resulting from the presence of chondroitin sulfate on TMD1-1O5.
11
- 20 The presence of a highly sulfated chondroitin side chain on TMD1-105 may provide a secondary (low-affinity) binding site for thrombin and may also act to sterically hinder anion exosite-dependent interaction of thrombin with other proteins and or negatively charged polysaccharides such as heparin. 35 - 36 The presence or absence of chondroitin sulfate, as described in the present studies, has profound effects on the ability of soluble TM analogues to inhibit the activation of HUVEC monolayers by thrombin. Although direct evidence that human TM contains chondroitin sulfate in vivo does not exist, experiments with cultured human and bovine endothelial cells indicate that the affinity of cell-surface TM for thrombin is decreased by /3-r>xylosides, inhibitors of chondroitin sulfate attachment to proteoglycans, suggesting that cell-surface TM is modified with chondroitin sulfate in vivo. 20 A number of glycosaminoglycan-binding proteins such as platelet factor 4 35 can inhibit the anticoagulant functions of TM, suggesting that platelet factor 4 release from activated platelets might decrease thrombin affinity by binding and neutralizing the chondroitin sulfate of human TM, thereby reducing the ability of TM to compete with other receptors at the endothelial cell surface for thrombin binding.
The studies outlined above all indicate that TM, hirudin, C-terminal hirudin peptides, fibrinogen, heparin, and thrombin receptors on platelets and endothelial cells may share common or overlapping binding sites within the anion-binding exosite region of thrombin. This anion-binding exosite may, therefore, be a critical structural motif involved in control of thrombin's bioregulatory functions both at the level of thrombosis and hemostasis and at the level of cellular activation. Whereas the ability of endothelial cell TM to inhibit thrombus propagation at the vessel wall is well appreciated, 1 our finding that soluble TM derivatives blocked thrombin receptor-mediated HUVEC activation suggests a further role for TM on the endothelial cell surface in vivo. HUVEC cell-surface TM is a highaffinity thrombin receptor with a K^ for a-thrombin between 0.1 and 0.5 nmol/L. 9 - 20 The thrombin receptor involved in stimulation of endothelial cell PGI 2 synthesis and permeability is of lower affinity (/C d >1 nmol/L 37 ). TM may effectively compete for thrombin binding, particularly at low thrombin concentrations (=1 nmol/L or less) and prevent the propagation of thrombinmediated endothelial cell activation in the vessel wall distal to the site of thrombus formation. Such a role for TM would be consistent with the known anti-inflammatory properties of activated protein C and protein S and would further emphasize the role of the protein C anticoagulant pathway in regulation of inflammatory responses. 38 In conclusion, our studies demonstrate that human TM can attenuate thrombin receptor-mediated activa-tion of human endothelial cells. The inhibitory potential of human TM is augmented by the presence of chondroitin sulfate, further emphasizing a critical role for posttranslational modification in the functions of this important thrombin-binding regulatory protein.
